Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CG Oncology (CGON) Non-Current Assets (2023 - 2025)

CG Oncology's Non-Current Assets history spans 3 years, with the latest figure at $32.1 million for Q4 2025.

  • For Q4 2025, Non-Current Assets rose 5371.38% year-over-year to $32.1 million; the TTM value through Dec 2025 reached $121.6 million, up 6163.85%, while the annual FY2025 figure was $32.1 million, 5371.38% up from the prior year.
  • Non-Current Assets reached $32.1 million in Q4 2025 per CGON's latest filing, down from $34.1 million in the prior quarter.
  • In the past five years, Non-Current Assets ranged from a high of $34.1 million in Q3 2025 to a low of $391000.0 in Q3 2024.
  • Average Non-Current Assets over 3 years is $14.3 million, with a median of $5.2 million recorded in 2023.
  • Peak YoY movement for Non-Current Assets: crashed 88.66% in 2024, then surged 8627.11% in 2025.
  • A 3-year view of Non-Current Assets shows it stood at $5.2 million in 2023, then plummeted by 88.66% to $587000.0 in 2024, then surged by 5371.38% to $32.1 million in 2025.
  • Per Business Quant, the three most recent readings for CGON's Non-Current Assets are $32.1 million (Q4 2025), $34.1 million (Q3 2025), and $28.4 million (Q2 2025).